1. Home
  2. HURA

as 11-05-2024 10:36am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Stocks

Nasdaq

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Founded: 2009 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 193.8M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 94.4K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.43 EPS Growth: N/A
52 Week Low/High: $2.83 - $23.73 Next Earning Date: 11-15-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: